Trials / Unknown
UnknownNCT03416517
Anlotinib and Irinotecan for Ewing Sarcoma
Anlotinib and Irinotecan for Advanced Ewing Sarcoma After Failure of Standard Multimodal Therapy
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 47 (estimated)
- Sponsor
- Peking University People's Hospital · Academic / Other
- Sex
- All
- Age
- 5 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma.
Detailed description
After standard multimodal therapy, the prognosis of relapsed and metastatic Ewing Sarcoma is dismal and unchanged over the last decades.Thus, the investigators explored the activity of anlotinib combined with irinotecan in patients with relapsed and metastatic Ewing Sarcoma after the failure of first-line chemotherapy with doxorubicin, vincristine, cyclophosphamide, ifosphamide and etoposide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Anlotinib | Anlotinib 12 or 8 mg/d po D1-14 q3w |
| DRUG | Irinotecan | Irinotecan 20 or 15mg/m\^2/d IV over 60 minutes on days 1-5 and 8-12, q3w |
Timeline
- Start date
- 2018-01-22
- Primary completion
- 2020-02-01
- Completion
- 2020-12-01
- First posted
- 2018-01-31
- Last updated
- 2019-02-15
Locations
5 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03416517. Inclusion in this directory is not an endorsement.